203 results
20FR12G/A
REPCF
Replicel Life Sciences Inc.
23 Jan 03
Initial registration of securities (foreign private issuers) (amended)
12:00am
.
These financial statements are the responsibility of the Company's management.
Our responsibility is to express an opinion on these financial statements based … of loss and deficit and cash flows
for the years then ended. These financial statements are the responsibility of
the company's management. Our
20FR12G/A
REPCF
Replicel Life Sciences Inc.
17 Jan 03
Initial registration of securities (foreign private issuers) (amended)
12:00am
are the
responsibility of the company's management. Our responsibility is to
express an opinion on these financial statements based on our audits
6-K
EX-99.1
REPCF
Replicel Life Sciences Inc.
22 May 14
Current report (foreign)
12:00am
.) accepts responsibility for the adequacy or accuracy of this press release.
This press release contains forward-looking information that involve … Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange Inc.) accepts responsibility for the adequacy or accuracy
6-K
EX-99.1
REPCF
Replicel Life Sciences Inc.
23 Jun 14
RepliCel Retains O&M Partners to Coordinate North American Focused Investor Marketing Campaign
12:00am
of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
##
6-K
EX-99.1
dp334v1
6 Jun 14
Replicel Life Sciences Inc. 6-K
12:00am
6-K
EX-99.1
p8az b5kyqtsli9z7y
25 Oct 17
Current report (foreign)
12:00am
6-K
EX-99.1
wzwxc38wies9b
21 Jan 15
RepliCel Life Sciences to Present at 11th Annual Phacilitate Cell & Gene Therapy Forum in Washington, DC
12:00am
6-K
EX-99.7
stfnm238jcuvo
18 Aug 21
Current report (foreign)
12:20pm
6-K
EX-99.1
y7b0k6ogpemz
17 May 22
Replicel Life Sciences Inc. Provides Default Status Update
6:51pm
6-K
EX-99.1
r054z4cp6 km8bh9n4v6
22 Apr 20
Replicel Postpones Filing of Annual Financial Statements and MD&A Due to COVID-19 Related Delays
1:56pm
6-K
EX-99.3
wx9uv8j
11 Sep 19
51-102F3 Material Change Report
12:13pm
6-K
EX-99.1
l6hx 7cmwsh4
2 Oct 14
Replicel Life Sciences 6-K
12:00am
6-K
EX-99.3
b160p1cz
13 Aug 21
RepliCel CEO Provides Corporate Update
12:00am
6-K
EX-99.1
ir0w6tsgpxh1uc 4g8z3
18 Oct 18
Current report (foreign)
11:03am
6-K
EX-99.1
uevyez
4 Sep 14
RepliCel to Present at Rodman & Renshaw’s 16th Annual
12:00am
6-K
EX-99.1
s6hlwcyq3mh u0uerx
27 Feb 14
Replicel Life Sciences Inc. Form 6-K
12:00am
6-K
EX-99.1
laitzrek5d7tgoxc9
9 Oct 14
RepliCel to Present Commercial and Clinical Update at BioJapan 2014 World Business Forum
12:00am
6-K
EX-99
6w658u
9 Jan 14
RepliCel to Commence Trading on the TSX Venture Exchange
12:00am